Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.43 |
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520802 | 0.95 | PDK4 (0.46) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL29864873 | 0.89 | PDK4 (0.52) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL522085 | 0.89 | PDK4 (0.52) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL29535433 | 0.88 | PDK4 (0.51) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL10036179 | 0.88 | PDK4 (0.51) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL13436409 | 0.87 | PDK4 (0.46) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL16385571 | 0.86 | PDK4 (0.51) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL31630903 | 0.86 | PDK4 (0.51) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL5004734 | 0.86 | PDK4 (0.51) | PDK4ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL282496 | 0.85 | PDK4 (0.50) | PDK4ALDH1A1LMNAMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| EP-2864289-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | Crown Bioscience Inc. (Taiwan) (CN) | 2015-04-29 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| WO-2014000418-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-01-03 | — | — | WO | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | BRAF, RAF1, ARAF | PDK4 1040/4885ALDH1A1 4211/4885LMNA 3911/4885 |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | PDK4 267/4885ALDH1A1 1554/4885LMNA 2845/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | PDK4 267/4885ALDH1A1 1554/4885LMNA 2845/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PDK4 685/4885ALDH1A1 779/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.